Cover Image
Market Research Report

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019

Published by GlobalData Product code 562801
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019
Published: October 1, 2019 Content info: 100 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2019" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q2 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents
Product Code: GDHC0550QD

Table of Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2019
    • 2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2019
    • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2019
    • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2019
    • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2019
  • 3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type
    • 3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2019
    • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2019
    • 3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2019
    • 3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2019
  • 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019
    • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2019
    • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2018 - Q2 2019
    • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019
    • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019
    • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2018 - Q2 2019
    • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2018 - Q2 2019
    • 4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019
  • 5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2019
    • 5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2019
    • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019
    • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2018 - Q2 2019
    • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2018 - Q2 2019
    • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2018 - Q2 2019
    • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2018 - Q2 2019
    • 5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2018 - Q2 2019
  • 6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
    • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2019
    • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2019
    • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2019
    • 6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2019
    • 6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2019
    • 6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2019
    • 6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2019
    • 6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2019
    • 6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2019
    • 6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2019
  • 7 Deal Summary by Geography
    • 7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2019
    • 7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2019
    • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2019
    • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2019
  • 8 Pharmaceuticals & Healthcare, Global, Top Advisors
    • 8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q2 2018 - Q2 2019
    • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q2 2018 - Q2 2019
  • 9 Further Information
    • 9.1 Methodology
    • 9.2 About GlobalData
    • 9.3 Contact Us
    • 9.4 Disclosure information
    • 9.5 Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 11
  • Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q2 2019 13
  • Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2019 14
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 19
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q2 2019 19
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q2 2018 - Q2 2019 20
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 22
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q2 2019 22
  • Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q2 2019 22
  • Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q2 2019 23
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 24
  • Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 25
  • Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q2 2019 26
  • Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q2 2019 27
  • Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 28
  • Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 29
  • Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q2 2018 - Q2 2019 30
  • Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 31
  • Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q2 2019 32
  • Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 33
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 35
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 36
  • Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019 37
  • Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2019 38
  • Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2019 38
  • Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q2 2019 38
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q2 2018 - Q2 2019 39
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018 - Q2 2019 41
  • Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2018 - Q2 2019 43
  • Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 44
  • Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2018 - Q2 2019 45
  • Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q2 2019 46
  • Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q2 2019 46
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q2 2019 47
  • Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 48
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q2 2018 - Q2 2019 50
  • Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q2 2018 - Q2 2019 52
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q2 2018 - Q2 2019 54
  • Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 56
  • Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 60
  • Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 63
  • Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 66
  • Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 69
  • Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 72
  • Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 75
  • Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 78
  • Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 80
  • Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 82
  • Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 85
  • Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 88
  • Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 91
  • Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 94
  • Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 96
  • Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q2 2018 - Q2 2019 97

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q2 2018 - Q2 2019 10
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q2 2019 12
  • Figure 3: Pharmaceuticals & Healthcare, Global, De
Back to Top